Hieff Trans™ RNAiBoost Transfection Reagent (RNAiMax alternative) _ 40807ES

YeasenSKU: 40807ES01

Size: 100 μL
Price:
Sale price$85.00

Shipping calculated at checkout

Stock:
In stock

Description

HieffTM RNAiBoost in vitro transfection reagent relies on an exclusive delivery platform to efficiently and precisely deliver siRNA into cells, achieving >90% target gene silencing even in hard-to-transfect systems such as primary cells, with operation completed in 5 minutes, specifically designed for knockdown in primary and other hard-to-transfect cell lines, compatible with serum and antibiotics, and no medium change required post-transfectionWrite information about product introduction.

Features

  • Higher transfection efficiency: Achieves >90% target gene knockdown even in hard-to-transfect primary cells
  • Lower siRNA requirement: Delivers high knockdown efficiency with siRNA concentrations as low as 2–50 nM
  • Simplified workflow: Complex formation in just 5 minutes; fully compatible with serum and antibiotics—no media change required

Components

Components No.

Name

40807ES01

40807ES03

40807ES04

40807-A

RNAiBoost Transfection Reagent

100 μL

0.75 mL

1.5 mL

40807-B

Enhancer

300 μL

3 × 0.75 mL

3 × 1.5 mL

Storage

This product should be stored at 2~8℃ for 1 years.

Figures

High Knockdown Efficiency

Figure 1. siRNA transfection across different cells using Booster DNA&RNA Transfection Reagent versus supplierT*. The result demonstrates superior siRNA transfection efficiency of Booster.

 Figure 1. siRNA transfection across different cells using Booster DNA&RNA Transfection Reagent versus supplier  T*. The result demonstrates superior siRNA transfection efficiency of Booster.

Figure 2: Hard-to-Transfect Cell Lines-STC-1
Figure 3: Hard-to-Transfect Cell Lines-HepG2
Figure 4: Hard-to-Transfect Cell Lines-HK-2

Documents:

Safety Data Sheet

40807_MSDS_HB260203_EN.PDF

Manuals

40807_Manual_Ver.EN20260203.pdf

Customer Cases:

Primary Cell Transfection Cases

Cell Type

Abbreviation

Nucleic Acid Type

Primary bone marrow-derived macrophages

BMDM

siRNA((6-Well Plate)

Primary human umbilical vein endothelial cells

HUVEC

siRNA

Primary bone marrow-derived macrophages

BMDM

siRNA(12-Well Plate)

 

Tumor Cell Transfection Cases

Cell Type

Abbreviation

Nucleic Acid Type

Human T-cell leukemia cell

CEMT-4

siRNA

Human hepatocellular carcinoma cell line

HePG2

siRNA

Human breast cancer cell

MCF-7

siRNA

Human monocytic leukemia cell

THP-1

siRNA(6-Well Plate)

Human monocytic leukemia cell

THP-1

siRNA(12-Well Plate)

 

Tissue Cell Transfection Cases

Cell Type

Abbreviation

Nucleic Acid Type

Human bronchial epithelial cell

BEAS-2B

siRNA

Human renal proximal tubular epithelial cell

HK-2

siRNA

Human hepatic stellate cell

LX2

siRNA

Mouse cardiac fibroblast

MCF

siRNA

Mouse embryonic fibroblast

NIH-3T3

siRNA

Mouse monocyte/macrophage cell

RAW264.7

siRNA(6-Well Plate)

Mouse monocyte/macrophage cell

RAW264.7

siRNA(24-Well Plate)

Rat bile duct epithelial cell

RBE

siRNA

Mouse intestinal endocrine cell

STC1

siRNA

Try it for free!

Get a free sample of RNAiBoost and validate its performance in your own lab.
👉 [Request Sample Now]. Worldwide Shipping!

Related Blog

Next-Gen siRNA Transfection | Achieve 90% Gene Knockdown with Ease

DNA Transfection?

The novel reagent here.

Payment & Security

American Express Apple Pay Diners Club Discover Google Pay Mastercard Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

You may also like

Inquiry

FAQ

The product is for research purposes only and is not intended for therapeutic or diagnostic use in humans or animals. Products and content are protected by patents, trademarks, and copyrights owned by Yeasen Biotechnology. Trademark symbols indicate the country of origin, not necessarily registration in all regions.

Certain applications may require additional third-party intellectual property rights.

Yeasen is dedicated to ethical science, believing our research should address critical questions while ensuring safety and ethical standards.